Skip to main content
SpringerLink
Log in

Dopaminerg-induzierte Psychosen und Halluzinationen bei Morbus Parkinson

  • Conference paper
Der multimorbide Parkinsonpatient

Zusammenfassung

Dopaminerg-induzierte Psychosen bei Parkinsonpatienten werden kontrovers diskutiert. Warum gerät ein kaum noch mobilisierbarer Patient im fortgeschrittenen Krankheitsstadium beim Auftreten einer Psychose in einen langdauernden On-Zustand, der selbst nach Absetzen der Dopaminagonisten für den Zeitraum dieses pharmakotoxischen Delirs anhält? Mit Nachlassen des Delirs wird ein solcher Patient zunehmend geordnet und parallel zunehmend unbeweglich, evtl. bis zum erneutem Erreichen des Off-Zustandes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Fénelon G, Mahieux F, Huon R, Ziégler M (2000) Hallucinations in Parkinson’s disease. Brain 123: 733–745

    Article  PubMed  Google Scholar 

  2. Goetz CG, Vogel C, Tanner CM, Stebbins GT (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51: 811–814

    Article  PubMed  CAS  Google Scholar 

  3. Mendis T, Barclay CL, Mohr E (1996) CNS drug-induced psychosis in Parkinson’s disease. Drugs 3: 166–174

    Google Scholar 

  4. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson’s disease patients. Neurology 52(suppl 3): S10–S13

    PubMed  CAS  Google Scholar 

  5. Ziegler B (1996) Zur Psychopathologie des Parkinson-Syndroms. Klinikarzt 9/25: 266–270

    Google Scholar 

  6. Melamed E, Friedberg G, Zoldan J (1999) Psychosis, Impact on the patient and family. Neurology 52(suppl 3): S14–S16

    PubMed  CAS  Google Scholar 

  7. Factor SA, Molho ES, Brown DL (1998) Acute delirium after withdrawal of amantadine in Parkinson’s disease. Neurology 50: 1456–1458

    Article  PubMed  CAS  Google Scholar 

  8. Graham JM, Grünewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson’s disease. Neurology 63: 434–440

    CAS  Google Scholar 

  9. Inzelberg R, Kipervasser S, Korczyn AD (1998) Auditory. Neurology 64: 533–535

    CAS  Google Scholar 

  10. Friedman JH (1999) Intravenous levodopa in hallucinating PD patients. Neurology 52: 219–220

    PubMed  CAS  Google Scholar 

  11. Makoff AJ, Graham JM, Arranz MJ, Forsyth J, Li T, Aitchison KJ, Shaikh S, Grünewald RA (2000) Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics 10: 43–48

    Article  PubMed  CAS  Google Scholar 

  12. Jonnalagada JR, Norton JW (2000) Letters to the editor. Neurology 23: 230–231

    Google Scholar 

  13. Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S (1999) Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. Neurology 246: 365–368

    Article  CAS  Google Scholar 

  14. Iansek R, Feniger H (1999) Successful psychotropic management of drug related psychosis in Parkinson’s disease. Journal of Clinical Neuroscience 6(6): 488–491

    Article  PubMed  CAS  Google Scholar 

  15. Friedman JH, Steward A, Factor DO (2000) Atypical antipsychotics in the treatment of druginduced psychosis in Parkinson’s disease. Review. Movement Disorders 15: 201–211

    Article  CAS  Google Scholar 

  16. Cummings J (1999) Managing psychosis in patients with Parkinson’s disease. New Engl J Med 340: 801–803

    Article  PubMed  CAS  Google Scholar 

  17. Millat B, Hay JM, Vallcur P, Fingerhut A, Fagniez PL, Schein M, Gecelter G (1999) Clozapine for drug-induced psychosis. New Engl J Med 341: 456

    Google Scholar 

  18. The Parkinson Study Group (1999) Low-dose Clozapine for the treatment of drug-induces psychosis in Parkinson’s disease. New Engl J Med 340: 757–763

    Article  Google Scholar 

  19. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K (2001) Clozapine for the treatment of drug-induced psychosis in Parksinson’s disease: Results of the 12 week open label extension in the PSYCLOPS trial. The Parkinson Study Group. Movement Disorders 16: 135–139

    CAS  Google Scholar 

  20. Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F (1997) Low dose of Clozapine in the treatment of dopaminergic psychosis in Parkinson’s disease. Clinical Neuropharmacology 20: 204–209

    Article  PubMed  CAS  Google Scholar 

  21. The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson’s disease. The Lancet 353: 2041–2042

    Article  Google Scholar 

  22. Auzou P, Özsancak C, Hannequin D, Moore N, Augustin P (1996) Clozapine for the treatment of psychosis in Parkinson’s disease: a review. Acta Neurol Scand 94: 329–336

    Article  PubMed  CAS  Google Scholar 

  23. Graas M, Diederich N (1997) Exogene Psychosen beim Morbus Parkinson und ihre Behandlung mit Clozapin. Nervenheilkunde 16: 122–131

    Google Scholar 

  24. Richard IH, Nutt J (2000) Worsening of motor function in Parkinson’s disease. Neurology 55: 748–749

    Article  PubMed  CAS  Google Scholar 

  25. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and Clozapine. Neurology 55: 789–794

    Article  PubMed  CAS  Google Scholar 

  26. Friedman JH, Goldstein S, Jacques C (1998) Substituting Clozapine for olanzapine. Clinical Neuropharmacology 21: 285–288

    PubMed  CAS  Google Scholar 

  27. Molho ES, Factor SA (1999) Worsening of motor features of parkinsonism with olanzapine. Movement Disorders 14: 1014–1016

    Article  PubMed  CAS  Google Scholar 

  28. Wolters EC, Janson ENH, Tuynman-Qua HG, Bergmans PLM (1996) Olanzapine in the treatment of dopaminomitic psychosis in patients with Parkinson’s disease. Neurology 47: 1085–1087

    Article  PubMed  CAS  Google Scholar 

  29. Aarsland D, Larsen JP, Lim NG, Tandberg E (1999) Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. Neuropsychiatry Clin 11: 392–394

    CAS  Google Scholar 

  30. Menza MMA, Palermo B, Mark M (1999) Quetiapine as an alternative to Clozapine. Annals of Clinical Psychiatry 11: 141–144

    PubMed  CAS  Google Scholar 

  31. Fernandez HH, Friedman JH, Jaques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Movement Disorders 14: 484–487

    Article  PubMed  CAS  Google Scholar 

  32. Friedman JH, Fernandez HH, Jacques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Neurology 52(6) suppl 2: A215

    Google Scholar 

  33. Targum SD, Abbott JL (2000) Efficacy of quetiapine in Parkinson’s patients with psychosis. Journal of Clin Psychopharmacology 20: 54–60

    Article  CAS  Google Scholar 

  34. Dewey RB, O’Suilleabhain PE (2000) Treatment of drug-induced psychosis with quetiapine and Clozapine in Parkinson’s disease. Neurology 55: 1753–1754

    Article  PubMed  Google Scholar 

  35. Weiner WJ, Minagar A, Shulman LM (2000) Quetiapine for L-dopa-induced psychosis in PD. Neurology 55: 899

    Google Scholar 

  36. Fernandez HH (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Movement Disorders 15: 579–586

    Article  PubMed  CAS  Google Scholar 

  37. Mohr E, Mendis T, Hildebrand K, De Deyn PP (2000) Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Movement Disorders 15: 1230–1237

    Article  PubMed  CAS  Google Scholar 

  38. Ling ZD, Stebbins GT, Carvey PM (1997) Risperidone in levodopa-induced psychosis. Movement Disorders 12: 610–612

    Article  Google Scholar 

  39. Leopold NA (2000) Risperidone treatment of drug-related psychosis in patients with parkinsonism. Movement Disorders 15: 301–304

    Article  PubMed  CAS  Google Scholar 

  40. Rich SS, Friedman JH, Ott BR (1995) Risperidone versus Clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. Clin Psychiatry 56: 556–559

    CAS  Google Scholar 

  41. Friedman JH, Ikeguchi K, Kuroda A (1996) Comments and Reply on Ikeguchi and Kuroda: mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Clin Neurosci 246: 106–107

    CAS  Google Scholar 

  42. Barbato L, Monge A, Stocchi F, Nordera G (1996) Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Functional Neurology 11: 4

    Google Scholar 

  43. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000) Rivastigmine in the treatment of dementia with lewy bodies: preliminary findings from an open trial. Int J Geriat Psychiatry 15: 387–392

    Article  CAS  Google Scholar 

  44. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV (2000) Better cognitive and Psychopathologic response to donepezil in patients prospectively diagnosed as dementia with lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15: 794–802

    Article  PubMed  CAS  Google Scholar 

  45. Moskovitz C, Moses H, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135: 669–675

    PubMed  CAS  Google Scholar 

  46. Sharf B, Moskovitz C, Lupton MD et al. (1978) Dream phenomena induced by chronic levodopa therapy. J Neural Transm 43: 143–151

    Article  PubMed  CAS  Google Scholar 

  47. Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM (1984) Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J 289: 1101–1103

    Article  CAS  Google Scholar 

  48. Aarsland D, Larsen JP, Cummings JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study. Arch Neurol 56: 595–601

    Article  PubMed  CAS  Google Scholar 

  49. Litvan I, Maclntyre A, Goetz CG, Wenning GK, Jellinger K (1998) Accuracy of the clinical diagnosis of Lewy body disease, Parkinson’s disease and dementia with Lewy bodies: a clinic pathologic study. Arch Neurol 55: 969–978

    Article  PubMed  CAS  Google Scholar 

  50. Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in Parkinsonism with Clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 235: 60–64

    Article  PubMed  CAS  Google Scholar 

  51. Rinne UK (1982) Brain neurotransmitter receptors in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, Boston, pp 59–74

    Google Scholar 

  52. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson’s disease. Arch Neurol 53: 1265–1268

    Article  PubMed  CAS  Google Scholar 

  53. Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505–2511

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. Bittkau
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik der Ruhr-Universität Bochum, St. Josef-Hospital, Gudrunstraße 56, 44791, Bochum, Germany

    Horst Przuntek  & Thomas Müller  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bittkau, S. (2002). Dopaminerg-induzierte Psychosen und Halluzinationen bei Morbus Parkinson. In: Przuntek, H., Müller, T. (eds) Der multimorbide Parkinsonpatient. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57512-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57512-9_14

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-7985-1353-2

  • Online ISBN: 978-3-642-57512-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation